XML 43 R33.htm IDEA: XBRL DOCUMENT v3.26.1
Non-Consolidated Affiliates (Tables)
 3 Months Ended
Mar. 31, 2026
Equity Method Investments and Joint Ventures [Abstract]  
Summary of Equity in Earnings and Distributions of Equity Method Investees
Equity in earnings is recorded within Equity in earnings of equity method investees on the condensed consolidated statements of operations and cash distributions are recorded within Distributions from equity method investees on the condensed consolidated statements of cash flows. The following tables summarize equity in earnings and cash distributions from our equity method investees (in thousands):

For the Three Months Ended March 31,
20262025
Equity in (earnings)/losses of equity method investees
The Legacy SLP Interest$(5,688)$(8,195)
The Avillion Entities(16,070)1,752 
Total$(21,758)$(6,443)
For the Three Months Ended March 31,
20262025
Distributions from equity method investees
The Legacy SLP Interest$6,059 $8,337 
Avillion I
13,396 13,396 
Avillion II(1)
26,573 27,925 
Total$46,028 $49,658 
(1)For the first quarter of 2026, amount includes approximately $10.3 million, representing our pro rata portion of the $22 million milestone payment Avillion II received from AstraZeneca following the FDA's approval of a supplemental NDA for Airsupra. For the first quarter of 2025, amount includes approximately $27.4 million, representing our pro rata portion of the $55 million milestone payment Avillion II received from AstraZeneca following Airsupra meeting the primary endpoint in the Phase 3 clinical trial.